Skip to content
10-Q/A

Quarterly Report

ALLOS THERAPEUTICS INC

0001104659-12-020832

← back to feed
Filed
Mar 26, 2012 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2011 · Aug 1, 2011 105.68M sh
Operating Cash Flow Q2 2011 · Jun 30, 2011 $10.82M
Operating Cash Flow Q2 2011 · Jun 30, 2010 −$39.64M
Short Term Investments Q2 2011 · Jun 30, 2011 $40.57M
Short Term Investments Q2 2011 · Dec 31, 2010 $50.33M
Cash And Equivalents Q2 2011 · Jun 30, 2011 $68.9M
Cash And Equivalents Q2 2011 · Dec 31, 2010 $48.16M
Cash And Equivalents Q2 2011 · Jun 30, 2010 $76.79M
Cash And Equivalents Q2 2011 · Dec 31, 2009 $141.19M
Stockholders Equity restated Q2 2011 · Jun 30, 2011 $87.1M
Stockholders Equity Q2 2011 · Dec 31, 2010 $98.2M
Current Liabilities restated Q2 2011 · Jun 30, 2011 $24.79M
Current Liabilities Q2 2011 · Dec 31, 2010 $22.56M
Current Assets Q2 2011 · Jun 30, 2011 $127.21M
Current Assets Q2 2011 · Dec 31, 2010 $113.17M
Total Assets Q2 2011 · Jun 30, 2011 $134.12M
Total Assets Q2 2011 · Dec 31, 2010 $120.76M
Sga Expense Q2 2011 · Jun 30, 2011 $20.16M
Sga Expense Q2 2011 · Jun 30, 2011 $37.71M
Sga Expense Q2 2011 · Jun 30, 2010 $20.52M
Sga Expense Q2 2011 · Jun 30, 2010 $38.45M
Net Income restated Q2 2011 · Jun 30, 2011 −$2.51M
Net Income restated Q2 2011 · Jun 30, 2011 −$17.72M
Net Income Q2 2011 · Jun 30, 2010 −$19.95M
Net Income Q2 2011 · Jun 30, 2010 −$40.5M
Operating Income restated Q2 2011 · Jun 30, 2011 −$2.54M
Operating Income restated Q2 2011 · Jun 30, 2011 −$17.78M
Operating Income Q2 2011 · Jun 30, 2010 −$20.02M
Operating Income Q2 2011 · Jun 30, 2010 −$40.63M
Revenue restated Q2 2011 · Jun 30, 2011 $34.43M
Revenue restated Q2 2011 · Jun 30, 2011 $45.29M
Revenue Q2 2011 · Jun 30, 2010 $7.89M
Revenue Q2 2011 · Jun 30, 2010 $15.29M